Varubi approved for nausea and vomiting associated with cancer chemo

the ONA take:

Rolapitant (Varubi) has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of highly emetogenic and moderately emetogenic chemotherapy-induced nausea and vomiting occurring in the delayed phase, according to a press release by Tesaro, Inc.

Rolapitant should be administered at a dose of 180 mg approximately 1 to 2 hours prior to chemotherapy administration in combination with a 5HT3 receptor antagonist, such as granisetron, and dexamethasone.

"While important strides in preventing nausea and vomiting associated with chemotherapy have been made, still up to half of patients receiving emetogenic cancer chemotherapy can experience delayed CINV," said Richard J. Gralla, M.D., Professor of Medicine at Albert Einstein College of Medicine in New York. "Because NK-1 receptors are key drivers of CINV, especially in the delayed Phase, NK-1 receptor antagonists such as Varubi, when combined with a 5-HT3 receptor antagonist and a corticosteroid, provide enhanced protection from CINV, and do so in the delayed timeframe where the most help is needed."

Adverse events occurring in 3% or more of patients include decreased appetite, neutropenia, dizziness, dyspepsia, urinary tract infection, stomatitis, and anemia.

Rolapitant is an NK-1 receptor antagonist similar to aprepitant (Emend), which is also indicated for the prevention of chemotherapy-induced nausea and vomiting.

Varubi approved for nausea and vomiting associated with cancer chemo
The FDA for the prevention of highly emetogenic and moderately emetogenic chemotherapy-induced nausea and vomiting.
TESARO, Inc. today announced that the U.S. FDA has approved Varubi™ (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
READ FULL ARTICLE From ir.tesarobio.com
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs